Sino Biopharmaceutical Limited (SEHK: 1177)
Health Care · Pharmaceuticals · HK
HK$5.41
-1.37% today · -31.5% 1Y
Sino Biopharmaceutical Limited (SEHK: 1177) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $12.28B and employs 22,838 people.
Over the last twelve months the share price has lost 31.5%, trading between 4.19 and 8.54.
Tweenvest scores Sino Biopharmaceutical Limited across four factors: quality 83/100, value 59/100, growth 42/100, dividend 67/100. Its strongest factor is quality.
1177 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $12.28B
- Revenue (TTM)
- $4.96B
- P/E
- 35.30
- EPS
- 0.13
- Dividend yield
- 2.55%
- Beta (5Y)
- 0.61
- 52-week high
- HK$8.54
- 52-week low
- HK$4.19
- Avg volume (3M)
- —
- Shares outstanding
- 17.81B
- Employees
- 22,838
- Next earnings
- —
About Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
- ISIN
- KYG8167W1380
- Founded
- 2000
- Listed since
- May 12, 2004
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| CSPC Pharmaceutical Group LimitedSEHK: 1093 | $13.22B | HK$9.09 | -2.15% |
| Corcept Therapeutics IncorporatedNasdaqCM: CORT | $13.10B | $121.20 | +0.01% |
| Ipsen S.A.ENXTPA: IPN | $13.10B | €143.50 | +0.56% |
| Orion OyjHLSE: ORNBV | $12.51B | €82.30 | +3.39% |
| Recordati Industria Chimica e Farmaceutica S.p.A.BIT: REC | $12.15B | €52.95 | -0.09% |
| Zydus Lifesciences LimitedNSEI: ZYDUSLIFE | $11.52B | Rs1,117.50 | -2.46% |
| Elanco Animal Health IncorporatedNYSE: ELAN | $11.45B | $22.78 | -0.61% |
| Laurus Labs LimitedNSEI: LAURUSLABS | $11.37B | Rs2,036.60 | +2.65% |
Figures last refreshed Oct 11, 2026.